Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Elicio Therapeutics
Elicio Therapeutics
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
oncology
clinical trials
Daiichi Sankyo
AstraZeneca
Enhertu
metastatic breast cancer
Gilead Sciences
Trodelvy
bladder cancer
GSK
Zejula
Jemperli
ovarian cancer
Roche
tiragolumab
Tecentriq
non-small cell lung cancer
Cue Biopharma
CUE-101
head and neck cancer
Elicio Therapeutics
ELI-002
solid tumors
Conditions are ripe for reverse mergers
EP Vantage
Fri, 02/24/23 - 08:48 am
M&A
reverse merger
Redx
Jounce Therapeutics
Pherecydes
Erytech
Flame Biosciences
Leap Therapeutics
Elicio Therapeutics
Angion
Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move
Fierce Biotech
Tue, 01/17/23 - 10:18 am
Elicio Therapeutics
NASDAQ
cancer vaccines
clinical trials
Angion Biomedica
An In-Depth Look at Innovation on Cancer Research Day
BioSpace
Sun, 09/26/21 - 11:24 pm
cancer
oncology
R&D
Cue Biopharma
Celyad Oncology
Fore Biotherapeutics
X4 Pharmaceuticals
Elicio Therapeutics
OSE Immunotherapeutics
Sotio
GigaGen
